Nuvation Bio (NYSE:NUVB) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 16.67 percent increase over losses of $(0.12) per share from the same period last year.
Nuvation Bio Q4 EPS $(0.10) Beats $(0.11) Estimate
Nuvation Bio (NYSE:NUVB) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 16.67 percent increase over losses of $(0.12) per share from the
Related Posts
Schlumberger CEO Olivier Le Peuch Says ‘We Have Been Behind The Curve In Supply’
Today, 9:14 AM
-Reuters Cera Week
Needham Maintains Buy on Esperion Therapeutics, Raises Price Target to $16
Today, 9:14 AM
Needham analyst Serge Belanger maintains Esperion Therapeutics (NASDAQ:ESPR) with a Buy and raises the price target from $12 to $16.